Trial Profile
A prospective, exploratory, single arm and single center clinical trail to evaluate the safety and efficacy of Apatinib Mesylate Tablets or combined with chemotherapy in advanced and recurrent and persistent cervical carcinoma
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Carcinoma; Cervical cancer
- Focus Adverse reactions; Therapeutic Use
- 21 Sep 2021 Results (n=24) presented at the 46th European Society for Medical Oncology Congress
- 04 Jan 2018 New trial record